Trial reportInternational journal of cardiology2013
Effect of inhaled iloprost on the exercise function of Fontan patients: a demonstration of concept.
Trial report in International journal of cardiology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 2 syntheses or guidelines pooled it, 89 citations in OpenAlex.
- Pharmacology Management in Improving Exercise Capacity of Patients with Fontan Circulation: A Systematic Review and Meta-analysis.Current cardiology reviews · 2022Pooled it
- Pulmonary vasodilator therapy after the Fontan procedure: a meta-analysis.Heart failure reviews · 2021Pooled it
- A Randomized, Controlled Pharmacokinetic and Pharmacodynamics Trial of Ambrisentan After Fontan Surgery.Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies · 2020Trial
- Results of the FUEL Trial.Circulation · 2020Trial
- Results of a phase I/II multi-center investigation of udenafil in adolescents after fontan palliation.American heart journal · 2017Trial
- New perspectives in the management of adults with congenital heart disease: insights from the 2025 ACHD Congress.European heart journal supplements : journal of the European Society of Cardiology · 2026Article
- Pathophysiology of endothelial dysfunction in Fontan circulation: from bench to bedside and back again.Angiogenesis · 2025Review
- Pulmonary Vasodilator Therapy in Patients With Fontan Circulation: A Meta-Analysis.Korean circulation journal · 2025Article
- Augmented Biphasic Breathing Using Sniff and an Oral Positive Expiratory Pressure Device (Sniff-PEP) in Fontan Patients.Pediatric cardiology · 2025Article
- The effects of standardized intravenous treprostinil in pulmonary arterial hypertension patients after total cavo-pulmonary connection procedure.European journal of medical research · 2024Article
- Surgical Modulation of Pulmonary Artery Shear Stress: A Patient-Specific CFD Analysis of the Norwood Procedure.Cardiovascular engineering and technology · 2024Article
- Medical Therapy for Heart Failure in Adult Congenital Heart Disease Patients.Structural heart : the journal of the Heart Team · 2024Review
- Unique Pulmonary Hypertensive Vascular Diseases Associated with Heart and Lung Developmental Defects.Journal of cardiovascular development and disease · 2023Review
- Exercise Pathophysiology and Testing in Individuals With a Fontan Circulation.CJC pediatric and congenital heart disease · 2023Review
- Cardiac Drugs in ACHD Cardiovascular Medicine.Journal of cardiovascular development and disease · 2023Review
- Exercising with a Single Ventricle: Limitations and Therapies.Journal of cardiovascular development and disease · 2022Review
- Medical Therapies for Heart Failure in Hypoplastic Left Heart Syndrome.Journal of cardiovascular development and disease · 2022Article
- Use of Pulmonary Arterial Hypertension Therapies in Patients with a Fontan Circulation: Current Practice Across the United Kingdom.Journal of the American Heart Association · 2022Article
- Current Treatment Options for the Failing Fontan Circulation.Current cardiology reviews · 2022Review
- Prevalent pharmacotherapy of US Fontan survivors: A study utilizing data from the MarketScan Commercial and Medicaid claims databases.American heart journal · 2022Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
backgroundExercise capacity following Fontan surgery is often depressed. An inability to reduce pulmonary vascular resistance appropriately during exercise may contribute to this phenomenon. The aim of this study was to determine whether administration of iloprost, a selective pulmonary vasodilator, would improve exercise function after Fontan procedure.
methodsDouble-blind, randomized, placebo controlled, crossover trial. Patients performed two cardiopulmonary exercise tests (CPX) separated by <1 month. A single nebulizer treatment (iloprost or placebo) was administered before each CPX.
results18 patients aged 12-49 (median 17) years were recruited. Mild throat discomfort developed in 10/18 patients during iloprost administration; all but 1 were able to complete treatment. No symptoms developed during placebo treatments (p<0.001). Two additional patients did not complete CPX: one with atrial flutter; another with developmental issues that precluded adequate CPX. In the 15 remaining subjects oxygen pulse (a surrogate for forward stroke volume) at peak exercise was higher following iloprost (median increase 1.2 ml/beat; p<0.001). Peak VO2 also rose (median increase 1.3 ml/kg/min; p<0.04). Nine patients had peak VO2 <30 ml/kg/min; each of these patients had higher peak VO2 following iloprost. Only 3/6 patients with peak VO2 >30 ml/kg/min had higher peak VO2 following iloprost (p<0.04).
conclusionsIloprost improves the peak oxygen pulse and peak VO2 of patients with Fontan physiology and appears to be particularly beneficial among patients with impaired exercise function. Treatment is associated with minor side effects. These findings support the concept of pulmonary vasodilator therapy in Fontan patients with limited functional capacity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.